A Real-world Study of Apatinib in the treatment for Inoperable or advanced gastric cancer in Shandong
Phase of Trial: Phase IV
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 04 Jun 2019 Results (n=732) assessing antitumor activity of Apatinib in advanced gastric cancer patients, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 18 Apr 2018 New trial record